anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To find an active ingredient as a new antimalarial medicine and clarify its action mechanism.  <P>SOLUTION: Gliotoxin which is an antibiotic substance which fungal Aspergillus produces is used as an active ingredient for the antimalarial medicine. The antimalarial medicine contains gliotoxin as an active ingredient. Specifically, proteasome activity of Plasmodium spp. is inhibited by gliotoxin to exhibit antimalarial effect. Further, e.g. the gliotoxin is made to act as an active ingredient of antimalarial medicine against chloroquine-sensitive or resistant Plasmodium spp. When the gliotoxin is used, the concentration free from cytotoxicity can be selected.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Disclosed are libraries of antibodies or antibody variable domains. The libraries include a plurality of different antibody variable domains generated by creating diversity in the CDR regions. Also disclosed are libraries comprising fusion polypeptides of one or more antibody variable domains and a heterologous protein such as a coat protein of a virus. Also disclosed are libraries comprising replicable expression vectors which include a gene encoding the fusion polypeptide and isolated host cells containing the expression vector. Also disclosed is a virus which displays the fusion polypeptide on the surface of the virus, libraries of the virus displaying a plurality of different fusion polypeptides on the surface of the virus and methods of using those compositions. Also disclosed are methods for generating the said libraries. The methods and compositions are useful for identifying novel antibodies that can be used therapeutically or as reagents. (62) Divided Out of 536826
If the implant is actually transplanted into the body for the purpose of regenerative medicine, a high level of safety is required in the sterilization treatment and packaging process, and if a new material is used, a great burden is imposed on the practitioner. On the other hand, conventional collagen is now used for transplantation in vivo in other applications, and has been practically successful in transplantation. However, the existing collagen has not been proven to effectively act as a cure for nerve damage. Furthermore, the effect of the existing LASCol on maintaining the survival of nerve cells is unknown. The neural cell culture material comprising LASCol has an excellent effect of maintaining the survival of neural cells. In addition, the therapeutic agent for nerve injury comprising LASCol can infiltrate intrinsic nerve cells or proliferate well even in the body, thereby rapidly extending and connecting nerve processes, and has a visibly improved effect on the BBB score for nerve injury.
Participants will be analyzed for Attention Deficit Hyperactive Disorder (ADHD) who are new users of methylphenidate monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
INTRODUCTION: The pathogenesis of pelvic organ prolapse (POP), an age-related disease, has not been fully elucidated. Therapeutic targets of POP are limited. Silencing information regulator 2 related enzyme 1 (SIRT1), a gene considered capable of regulating oxidative stress and cellular senescence, has been widely demonstrated involved in aging and age-related diseases. The present study aimed to explore the role of SIRT1 in POP in vivo and in vitro.
METHODS: Expression levels of SIRT1 in uterosacral ligament (USL) tissues from patients with or without POP were measured using immunohistochemical assays. SRT1720, a SIRT1 agonist, was used to upregulate SIRT1, and hydrogen peroxide (H2O2) was used to establish an oxidative stress model in human uterosacral ligament fibroblasts (hUSLFs). The effects of SIRT1 on cell viability, apoptosis, senescence, and reactive oxygen species (ROS) levels were detected, respectively. Western blot assays were used to examine expression levels of apoptosis- and senescence-associated biomarkers. Unpaired Student's t test, Mann-Whitney U test, χ2 test, and one-way ANOVA were performed for determining statistically significant differences.
RESULTS: Compared to the control group, expression levels of SIRT1 were downregulated in USL tissues and hUSLFs from patients with POP, and associated with stage (p < 0.05). hUSLFs of patients with POP had lower growth rates (p < 0.0001) than those of the control group, which were improved by upregulating SIRT1 (p < 0.05). The senescent proportion was higher in the POP group than the control group (43.63 ± 10.62% vs. 4.84 ± 5.32%, p < 0.0001), which could be reduced by upregulating SIRT1 (p < 0.0001). High ROS levels in the POP group were also alleviated by SRT1720. H2O2 exposure increased ROS levels, inhibited proliferation, and triggered apoptosis and senescence in hUSLFs of patients without POP in a concentration-dependent manner. Further, these damages were alleviated by pretreatment with SRT1720.
CONCLUSIONS: SIRT1 is downregulated in patients with POP, and the development of SIRT1 activators or agonists may have applications in the treatment and prevention of POP through antioxidative stress and antisenescence effects.
Acute pulmonary embolism (APE) is a thromboembolism situation that can be central or peripheral. APE risk analysis and classification are essential for therapy planning. Our aim is to determine the novel MAPH score (including age, mean platelet volume (MPV), total protein, and hematocrit parameters) that can distinguish APE subtypes. Our retrospective cohort analysis includes 97 APE patients referred to the emergency medicine department who underwent pulmonary computed tomography angiography (CTA) in 24 h from 2020 to 2022. The hospital information system provided demographic, clinical, laboratory, and pulmonary CTA data. APE was classified into central (46 patients) and peripheral (51 patients) depending on the area of vascular involvement. The central APE group had higher hypertension (HT) (67.4%) and atrial fibrillation (AF) (39.1%) incidence than the peripheral APE group (all p values > 0.05). The central APE had higher total protein and platelet counts (p = 0.003 and p = 0.036), but peripheral APE had higher troponin values (p = 0.029). Central APE had 2.17 ± 0.85 MAPH and peripheral APE 1.76 ± 0.95 (p = 0.029). HT, AF, platelet count, and MAPH score differed significantly in univariate logistic regression (all p values < 0.05). However, only platelet count varied in multivariate logistic regression (p = 0.042). ROC curve analysis revealed that the MAPH score predicts central APE with 83% sensitivity and 45% specificity at a cut-off level of 1.5. The new MAPH score as an indicator of blood viscosity may distinguish between central and peripheral APE. Our result is significant, especially for centers with limited examinations, as it may accelerate the diagnosis and treatment processes. We think that our results might guide future investigations.
Revascularization will be performed via either Percutaneous Coronary Intervention or Coronary Artery Bypass Graft, and the selection of the specific procedure will be at the discretion of the patient and their physician(s). Patients will be followed for one year after randomization. Follow-up visits will occur at Baseline, Day 105, and Day 365. At each visit, a rest-stress PET assessment will be performed, and adverse events related to study procedures and cardiac disease will be captured.
Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
The present invention relates to a process for producing eggs with low cholesterol level. Different concentrations of fermented red mold rice are added to hens feeds. The fermented red mold rice contains Monacolin K, which has an effect on reducing cholesterol level. The cholesterol level in eggs produced by the present process is much lower than that in eggs produced by the prior art process. Furthermore, the serum triglyceride of hens is reduced. People are paying more attention to health, thus lowering consumption of high cholesterol food. Since cholesterol in eggs accounts for more than 50% of daily take-up, consumption of egg can hardly increase. Therefore, low cholesterol eggs can not only be beneficial to the public's health, but also bears business advantage.
Participants in this arm will receive dental implants and single crowns made from lithium disilicate (e.max). The study will evaluate the biocompatibility of e.max by measuring inflammatory markers and clinical outcomes, including bleeding on probing and pocket depth, at 3 and 6 months post-implantation.
All 10 infants will receive active taVNS during breastfeeding sessions. There is no randomization or blinding involved.
Continue standard BMA frequency (every 4 or 12 weeks) as administered previously. If a change in BMA frequency (every 4 weeks to every 12 weeks OR every 12 weeks to every 4 weeks) was prescribed by the physician, this would still be considered on protocol treatment.
The invention discloses an oil-in-water type pargyline and asarum oil nanoemulsion antihypertensive medicine and a method for preparing the same. The nanoemulsion antihypertensive medicine is characterized in that the grain size of the nanoemulsion antihypertensive medicine is between 22.2-60.1 nanometers, and the mean grain size is 39.2 nanometers. The nanoemulsion antihypertensive medicine comprises the following raw materials by mass percent: 1%-18% of pargyline, 15%-40% of surfactant, 1%-25% of cosurfactant, 1%-20% of asarum and the balanced of distilled water. The nanoemulsion has small emulsion droplet particles, uniform distribution, small viscosity and good liquidity. The nanoemulsion organically combines the water-soluble medicine pargyline and the fat-soluble asarum oil together, so the dissolution and infiltration capacities of the asarum oil are improved, and the stability and pharmaceutical effect of the pargyline are enhanced. After the pargyline and the asarum oil are prepared into the nanoemulsion, the advantages of the pargyline and the asarum oil are combined together, so the antihypertensive effect is obviously improved, the pharmaceutical half-life period of the antihypertensive medicine is prolonged, and the medicine administration times are reduced.
BACKGROUND: Stress cardiomyopathy (SCM) is an acute heart failure syndrome characterized by transient, usually reversible left ventricular systolic dysfunction with normal or enhanced basal compensatory wall motion abnormalities involving the left ventricular anterior septum and apex, resulting in a "ballooning" appearance. However, it has rarely been reported in patients undergoing spinal surgery.
CASE PRESENTATION: We report a case of severe stress cardiomyopathy in a scoliosis patient with pectus excavatum who underwent spinal corrective surgery. During the wake-up period, circulatory collapse occurred. After multidisciplinary consultation, the patient was diagnosed with stress cardiomyopathy. At last, she had a good prognosis after a series of treatments including ECMO.
CONCLUSION: Stress cardiomyopathy is a reversible but uncommon condition. It can cause death if it is not diagnosed in time. Consequently, this report should improve the awareness of orthopedists and anesthesiologists for timely identification and management. For patients with potential risk factors, timely preoperative intervention should be performed to reduce the occurrence of stress cardiomyopathy.
The invention discloses a traditional Chinese medicine extract with a matrix metalloproteinase inhibiting function, a preparing method thereof, and an application thereof. The traditional Chinese medicine extract is extracted from a traditional Chinese medicine composition composed of rhubarb, purslane, and clove. In the traditional Chinese medicine composition, the mass ratio of rhubarb to purslane to clove is 30-60:20-50:10-30. The preparation method comprises steps that: rhubarb, purslane, and clove are mixed according to the ratio; water is added to the mixture, and the mixture is boiled and extracted; when extraction is finished, the mixture is cooled and filtered; a filtrate is subject to centrifugation and pump filtration, and a supernatant is obtained, such that the traditional Chinese medicine extract is obtained. According to the invention, the extraction and separation method of the traditional Chinese medicine extract is simple, the purity of an obtained product is high, and the quality of the product is greatly improved. As a result of functional tests, the extract provides relatively good matrix metalloproteinase inhibiting function, a skin aging retarding function, and a skin roughness ameliorating function.
1. An increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam and meprobamate) during the first trimester of pregnancy has been suggested in several studies. Because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physicians about the desirability of discontinuing the drug.



Withdrawal symptoms of the barbiturate type have occurred after the discontinuation of benzodiazepines (see DRUG ABUSE AND DEPENDENCE section).
BACKGROUND: Kidney transplantation is the optimal renal replacement therapy for children with end-stage renal disease; however, delayed graft function (DGF), a common post-operative complication, may negatively impact the long-term outcomes of both the graft and the pediatric recipient. However, there is limited research on DGF in pediatric kidney transplant recipients. This study aims to develop a predictive model for the risk of DGF occurrence after pediatric kidney transplantation by integrating donor and recipient characteristics and utilizing machine learning algorithms, ultimately providing guidance for clinical decision-making.
METHODS: This single-center retrospective cohort study includes all recipients under 18 years of age who underwent single-donor kidney transplantation at our hospital between 2016 and 2023, along with their corresponding donors. Demographic, clinical, and laboratory examination data were collected from both donors and recipients. Univariate logistic regression models and differential analysis were employed to identify features associated with DGF. Subsequently, a risk score for predicting DGF occurrence (DGF-RS) was constructed based on machine learning combinations. Model performance was evaluated using the receiver operating characteristic curves, decision curve analysis (DCA), and other methods.
RESULTS: The study included a total of 140 pediatric kidney transplant recipients, among whom 37 (26.4%) developed DGF. Univariate analysis revealed that high-density lipoprotein cholesterol (HDLC), donor after circulatory death (DCD), warm ischemia time (WIT), cold ischemia time (CIT), gender match, and donor creatinine were significantly associated with DGF (P < 0.05). Based on these six features, the random forest model (mtry = 5, 75%p) exhibited the best predictive performance among 97 machine learning models, with the area under the curve values reaching 0.983, 1, and 0.905 for the entire cohort, training set, and validation set, respectively. This model significantly outperformed single indicators. The DCA curve confirmed the clinical utility of this model.
CONCLUSIONS: In this study, we developed a machine learning-based predictive model for DGF following pediatric kidney transplantation, termed DGF-RS, which integrates both donor and recipient characteristics. The model demonstrated excellent predictive accuracy and provides essential guidance for clinical decision-making. These findings contribute to our understanding of the pathogenesis of DGF.
The invention belongs to the field of traditional Chinese medicine, and discloses a medicament for treating pulpitis. The medicament is prepared by the following bulk drugs by weight: 2-5 parts of root of kudzu vine, 1-4 parts of cimicifuga foetida, 1-3 parts of asarum, 1-2 parts of cassia twig, 4-7 parts of Ligusticum wallichii, 2-5 parts of radix sileris, 7-10 parts of Herba schizonepetae, 7-10 parts of cortex moutan, 8-12 parts of Flos Sophorae, 5-7 parts of Radix Angelicae dahuricae and 2-5 parts of licorice. The invention verifies 110 cases of patients with pulpitis, and all patients are in line with the diagnostic criteria of pulpitis. After diagnosis, the patients are divided into two groups; a treatment group (54 cases) comprises 26 cases of male patients and 28 cases of female patients at the age of 30-59, with course of disease for 1-2 years; a control group ( 56 cases ) comprises 29 cases of male patients and 27 cases of female patients at the age of 32-61, with course of disease for 1-2 years. Results show that comparison of the treatment group and the control group has significant difference, indicating that the treatment effect of the treatment group is better than the control group. Each dose of medicine is decocted into 450 ml of soup, the patient takes 150 ml of the soup each time 1 h after each meal for three times a day. The technical problem to be solved by the invention is to provide a medicament for the treatment of pulpitis, and the medicament has the advantages of reasonable prescription, no side effect and remarkable curative effect.
Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. About 6 teaspoons of blood will flow through the blood circuit, and the excess fluid will slowly be collected in the collection bag. The exact length of time of aquapheresis treatment is determined by how much fluid needs to be removed and how fast it can be removed. The average treatment is about 24 hours but can extend up to 7 days. About 6 liters or 13 pounds will be removed.
Disease modeling using human induced pluripotent stem cells (hiPSCs) from patients with genetic disease is a powerful approach for dissecting pathophysiology and drug discovery. Nevertheless, isogenic controls are required to precisely compare phenotypic outcomes from presumed causative mutations rather than differences in genetic backgrounds. Moreover, 2D cellular models often fail to exhibit authentic disease phenotypes resulting in poor validation in vitro. Here we show that a combination of precision gene editing and bioengineered 3D tissue models can establish advanced isogenic hiPSC-derived cardiac disease models, overcoming these drawbacks. To model inherited cardiac arrhythmias we selected representative N588D and N588K missense mutations affecting the same codon in the hERG potassium channel gene KCNH2, which are reported to cause long (LQTS) and short (SQTS) QT syndromes, respectively. We generated compound heterozygous variants in normal hiPSCs, and differentiated cardiomyocytes (CMs) and mesenchymal cells (MCs) to form 3D cardiac tissue sheets (CTSs). In hiPSC-derived CM monolayers and 3D CTSs, electrophysiological analysis with multielectrode arrays showed prolonged and shortened repolarization, respectively, compared to the isogenic controls. When pharmacologically inhibiting the hERG channels, mutant 3D CTSs were differentially susceptible to arrhythmic events than the isogenic controls. Thus, this strategy offers advanced disease models that can reproduce clinically relevant phenotypes and provide solid validation of gene mutations in vitro.
The invention discloses an alcohol-decomposing enzyme protein capable of decomposing ethanol and acetaldehyde and application thereof, wherein the alcohol-decomposing enzyme protein comprises at least one alcohol-decomposing protein region and at least one acetaldehyde-decomposing protein region, one alcohol-decomposing protein region is derived from human alcohol dehydrogenase, and the amino acid sequence is shown as SEQ ID NO. 1; and/or a protein region for decomposing acetaldehyde is derived from human acetaldehyde dehydrogenase, and the amino acid sequence is shown as SEQ ID NO. 2 or 3; or two protein tags, namely a protein tag Strep II, the amino acid sequence of which is shown as SEQ ID NO. 4; a protein tag HIS6 has an amino acid sequence shown in SEQ ID NO. 5. The invention obtains the anti-alcohol enzyme protein through a modern molecular biology method, can decompose ethanol and acetaldehyde, accelerates ethanol metabolism, and provides a new choice for reducing harm of drinking to human body and protecting human health.
We present two cases, in which end-of-life patients were inadvertently treated with bolus infusions of undiluted subcutaneous levetiracetam. The patients were treated for three and four days respectively. In both cases, the course of treatment was uneventful. Especially, no seizures, nor local irritation was observed. Administration of undiluted subcutaneous levetiracetam as intermittent bolus infusions by hand holds alluring properties for end-of-life patients. Amongst others reducing patient discomfort, increasing freedom of movement, and accessibility to essential seizure prophylaxis by eliminating the need for a syringe driver, thereby helping accommodate many patients wish to die in their own home. However, pharmacokinetics, efficacy, and safety, including the optimum dilution and administration time of the subcutaneous preparation remains to be determined in clinically controlled trials.
Following baseline assessment, the PI, a BA-trained, licensed occupational therapist will deliver a 10-session manualized program in the participants' homes to ensure optimal uptake of the active ingredients and integration into daily life routines. This intervention occurs over 10 weeks. The intervention manual will include educational materials for the 4-step approach, and worksheets for goal setting and developing daily routines. In the 1st BA-OT session, the PI will collect baseline assessments and use Canadian Occupational Performance Measure (COPM) data to facilitate goal setting. The top 5 participant-selected goals chosen will be the subject of the 4-step process in sessions 2 - 10. At least one goal must be related to improving physical activity routines; each participant will receive a Fitbit Charge 5 to self-monitor fitness progress. The unbiased evaluator will carry out follow-up assessments at 10 weeks and 22 weeks with participants in both conditions.
The healthy human brain is a complex, dynamical system which is hypothesized to lie near a phase transition at rest - at the boundary between order and chaos. Proximity to this critical point is functionally adaptive as it affords maximal flexibility, dynamic range, and information handling capacity, with implications for working memory function. Divergence from this critical point has become correlated with diverse forms of psychopathology and neuropathy suggesting that distance from a critical point is both a potential biomarker of disorder and also a target for intervention in disordered brains. The Investigators have further hypothesized that subjective cognitive effort is a reflection of sub-criticality induced by engagement with demanding tasks.

A key control parameter determining distance from criticality in a resting brain is hypothesized to be the balance of cortical excitation to inhibition (the "E/I balance"). Transcranial magnetic stimulation is a widely used experimental and clinical tool for neuromodulation and theta-burst stimulation (TBS) protocols are thought to modulate the E/I balance. Here the Investigators test whether cortical dynamics can be systematically modulated away from the critical point with continuous theta-burst stimulation (cTBS), which is thought to decrease the E/I balance, and thereby impact on working memory function and subjective cognitive effort during performance of the working memory tasks.